All articles tagged with #daraxonrasib
A promising pancreatic cancer therapy, daraxonrasib from Revolution Medicines, has sparked a rapid wave of patient inquiries and clinic access discussions in the US as doctors rush to coordinate expedited FDA review and company-led enrollment; early trial data show a substantial survival improvement compared with standard chemotherapy, but the treatment is not a cure and access involves a multi-step process.
A new pancreatic cancer drug, daraxonrasib, paired with chemotherapy, nearly doubles survival in advanced disease. In Phase 3, overall survival was 13.2 months with the combo vs 6.7 months with chemo alone, and earlier data showed progression-free survival around 8 months at the highest dose. The FDA has fast-tracked the drug and allowed expanded access, with potential use beyond KRAS-mutant tumors and possible earlier-line therapy consideration.
The FDA has approved an expanded-access protocol for the investigational pancreatic cancer drug daraxonrasib, allowing eligible patients with metastatic pancreatic ductal adenocarcinoma to access it before full approval. In clinical data, patients taking daraxonrasib showed a median survival of about 13 months versus six months with chemotherapy, and supporters like former Sen. Ben Sasse have reported improved pain and tumor shrinkage. The 300 mg daily pill works by blocking a signal that drives cancer growth, and the FDA’s April 30 protocol approval aims to give seriously ill patients earlier access while trials continue.
Former U.S. senator Ben Sasse, diagnosed with metastatic pancreatic cancer, joined Revolution Medicines’ frontline trial of daraxonrasib. Preliminary topline data show the drug can markedly extend survival versus chemotherapy in second-line use, and Sasse reports dramatic drops in the tumor marker CA 19-9 and meaningful pain relief, with frontline use potentially even more beneficial, signaling a potential major advance in pancreatic cancer care.
In a trial for metastatic pancreatic cancer, Revolution Medicines' targeted pill daraxonrasib extended median overall survival to 13.2 months versus 6.7 months with chemotherapy, a dramatic near-doubling that experts described as very impressive.
Revolution Medicines announced that its pancreatic cancer drug daraxonrasib met all primary and secondary endpoints in a Phase 3 trial, nearly doubling median overall survival (13.2 months vs 6.7 months) and reducing the risk of death by about 60% versus chemotherapy, prompting an FDA filing using a Commissioner’s National Priority Voucher; safety was manageable and the company is pursuing second-line use and trials in newly diagnosed patients.
Former Nebraska senator Ben Sasse discusses his metastasized Stage 4 pancreatic cancer and other cancers in a candid interview, saying he has months to live but intends to redeem the time. He’s taking the experimental drug daraxonrasib, which has reduced tumor volume by about 76% though some tumors remain, and continues working and hosting his podcast while prioritizing time with his family amidst his health struggles.
A new KRAS inhibitor drug, daraxonrasib, shows promising results in clinical trials for pancreatic cancer, offering hope for improved survival and quality of life for patients with this deadly disease, with the potential for faster approval due to government designations.